Serum C-reactive protein and plasma homocysteine levels are associated with hormone therapy use and other factors: A population-based study of middle-aged Australian-born women

Climacteric

Volumn 8, Issue 3, 2005, Pages 263-270

  Guthrie, J R ^a   Clark, M S ^a   Dennerstein, L ^a   Burger, H G ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Body mass index; C reactive protein; Exercise; Homocysteine; Hormone therapy; Statins; Women

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; FOLLITROPIN; HOMOCYSTEINE; STATINE DERIVATIVE;

ADULT; ARTICLE; AUSTRALIA; BLOOD SAMPLING; BODY MASS; EXERCISE; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SMOKING;

AUSTRALIA; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; EXERCISE; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HORMONE REPLACEMENT THERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SMOKING;

EID: 24044523543     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130500162611     Document Type: Article

References (40)

1. Ridker PM, Cushman M, Stampfer MJ, et al. Inflamation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9
2. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43
3. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-610
4. van Baal WM, Kenemans P, van der Mooren MJ, et al. Increased C-reactive protein during short-term hormone replacement therapy in healthy women. Thromb Haemost 1999;81:925-8
5. Ridker PM, Hennekens CH, Rifai N, et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-16
6. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study. Circulation 1999;100:717-22
7. Pradhan A, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease. JAMA 2002;288:980-7
8. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5
9. Sites CK, Toth MJ, Cushman M, et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002;77:128-35
10. Tchernof A, Nolan A, Sites CK, et al. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002;105:564-9
11. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trail and cohort study. JAMA 2001;286:64-70
12. Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003;169:155-8
13. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circulation Res 2001;89:763-71
14. Feldman M, Jialal I, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a high sensitive C-reactive protein assay. J Am Coll Cardiol 2001;37:2036-41
15. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Current Cardiol Rep 1999;1:99-104
16. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-13
17. Magyar MT, Szikszai Z, Balla J, et al. Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke 2003;34:58-63
18. Van Guldener C, Nanayakkara PW, Stehouwer CD. Homocysteine and blood pressure. Curr Hypertens Rep 2003;5:26-31
19. O'Connor JJ, Meurer LN. Should patients with coronary disease and high homocysteine take folic acid? J Fam Pract 2003;52: 16-18
20. Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis 2000;149:163-8
21. Chiantera V, Sarti CD, Fornaro F, et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286-91
22. Mathers CD, Vos ET, Stevenson CE, et al. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000;172:592-6
23. Barrett-Connor E. An epidemiologist looks at hormones and heart disease in women. J Clin Endocrinol Metab 2003;88:4031-2
24. Guthrie JR, Taffe JR, Lehert P, et al. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004;11:315-22
25. Dennerstein L, Smith AMA, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232-6
26. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. J Clin Endocrinol Metab 1995;80:3537-45
27. Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril 2001;76:874-8
28. SPSS for Windows. 2003 Statistical package for social sciences. Version 12.0. Chicago, III: SPSS Inc.
29. Barinas-Mitchell E, Cushman M, Meilahn EN, et al. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy menopausal women. Am J Epidemiol 2001;153:1094-101
30. Davidson S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8
31. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
32. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
33. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025-30
34. Manns PJ, Williams DP, Snow CM, et al. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement. Am J Human Biol 2003;15:91-100
35. Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA Homocysteine. V. DACH_LIGA homocysteine (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-403
36. Maden JS, Kristensen SR, Klitgaard NA, et al. Effect of long-term hormone replacement therapy on plasma homocysteine levels in postmenopausal women: a randomized controlled study. Am J Obstet Gynecol 2002;187:33-9
37. Celik H, Ayar A, Tug N, et al. Effects of tibolone on plasma homocysteine levels in postmenopausal women. Fertil Steril 2002;78:347-50
38. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501
39. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005;165:221-6
40. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999;149:261-7